Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
Eligible Applicants
Indian/Native American Tribal Governments (Other than Federally Recognized)Eligible Agencies of the Federal GovernmentU.S. Territory or PossessionFaith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions)